These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24715586)

  • 1. Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.
    Andersson C; Oji Y; Ohlson N; Wang S; Li X; Ottander U; Lundin E; Sugiyama H; Li A
    Cancer Med; 2014 Aug; 3(4):909-18. PubMed ID: 24715586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Kunze CA; Dietel M; Braicu I; Letsch A; Darb-Esfahani S
    Gynecol Oncol; 2016 Mar; 140(3):494-502. PubMed ID: 26721227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WT1 IgG antibody for early detection of nonsmall cell lung cancer and as its prognostic factor.
    Oji Y; Kitamura Y; Kamino E; Kitano A; Sawabata N; Inoue M; Mori M; Nakatsuka S; Sakaguchi N; Miyazaki K; Nakamura M; Fukuda I; Nakamura J; Tatsumi N; Takakuwa T; Nishida S; Shirakata T; Hosen N; Tsuboi A; Nezu R; Maeda H; Oka Y; Kawase I; Aozasa K; Okumura M; Miyoshi S; Sugiyama H
    Int J Cancer; 2009 Jul; 125(2):381-7. PubMed ID: 19384943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide.
    Oji Y; Hashimoto N; Tsuboi A; Murakami Y; Iwai M; Kagawa N; Chiba Y; Izumoto S; Elisseeva O; Ichinohasama R; Sakamoto J; Morita S; Nakajima H; Takashima S; Nakae Y; Nakata J; Kawakami M; Nishida S; Hosen N; Fujiki F; Morimoto S; Adachi M; Iwamoto M; Oka Y; Yoshimine T; Sugiyama H
    Int J Cancer; 2016 Sep; 139(6):1391-401. PubMed ID: 27170523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
    Zarychta E; Lepinay K; Szubert S; Jozwicki J; Misiak J; Brozyna AA; Kosinska-Kaczynska K; Lewandowska A; Malicka E; Makarewicz A; Rhone P; Jozwicki W
    Folia Histochem Cytobiol; 2020; 58(3):198-207. PubMed ID: 32960974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.
    Köbel M; Kalloger SE; Boyd N; McKinney S; Mehl E; Palmer C; Leung S; Bowen NJ; Ionescu DN; Rajput A; Prentice LM; Miller D; Santos J; Swenerton K; Gilks CB; Huntsman D
    PLoS Med; 2008 Dec; 5(12):e232. PubMed ID: 19053170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers.
    Dobrzycka B; Terlikowski SJ; Kinalski M; Kowalczuk O; Niklinska W; Chyczewski L
    Ann Oncol; 2011 May; 22(5):1133-1140. PubMed ID: 21098618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients.
    Heimes AS; Schmidt M; Jäkel J; Almstedt K; Gebhard S; Weyer-Eiberich V; Elger T; Krajnak S; Brenner W; Hasenburg A; Battista MJ
    Arch Gynecol Obstet; 2019 Jan; 299(1):239-246. PubMed ID: 30357498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor α in high-grade serous ovarian carcinoma.
    Taube ET; Denkert C; Sehouli J; Unger U; Kunze CA; Budczies J; Dietel M; Braicu E; Darb-Esfahani S
    Hum Pathol; 2017 Sep; 67():30-36. PubMed ID: 28414091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma: A Reclassification Study by the Spanish Group for Ovarian Cancer Research (GEICO).
    Leskela S; Romero I; Cristobal E; Pérez-Mies B; Rosa-Rosa JM; Gutierrez-Pecharroman A; Santón A; Gonzalez BO; López-Reig R; Hardisson D; Vera-Sempere F; Illueca C; Vieites B; López-Guerrero JA; Palacios J; Poveda A
    Am J Surg Pathol; 2020 Feb; 44(2):149-161. PubMed ID: 31498173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
    Karamurzin Y; Leitao MM; Soslow RA
    Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative CA-125 Values as a Predictive Factor for the Postoperative Outcome in Primary Serous Ovarian Cancer.
    Muallem MZ; Parashkevova A; Almuheimid J; Richter R; Diab Y; Braicu EI; Sehouli J
    Anticancer Res; 2017 Jun; 37(6):3157-3161. PubMed ID: 28551658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
    Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
    Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
    Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
    J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-infiltrating cytotoxic T lymphocytes as independent prognostic factor in epithelial ovarian cancer with wilms tumor protein 1 overexpression.
    Vermeij R; de Bock GH; Leffers N; Ten Hoor KA; Schulze U; Hollema H; van der Burg SH; van der Zee AG; Daemen T; Nijman HW
    J Immunother; 2011; 34(6):516-23. PubMed ID: 21654520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.